8k - Shire pays 11.5M for ROP rights- Form 8-K for INSMED INC 4/30
the Company amended the Premacure License Agreement to provide Premacure with an option to obtain all of the Company's right to receive revenues from the commercialization of IGF-1 under the Premacure License Agreement in exchange for a cash payment to the Company of $11.5 million (the "Buyout Amount").
Premacure exercised this option on April 29, 2013. Premacure is obligated to pay the Buyout Amount to the Company in full within ten days after the date of exercise. As a result of option exercise, the Company will not be entitled to any future royalties from Premacure, and Premacure will assume the Company's royalty obligations to other parties.